Hong Wan

Hong Wan

Company: ALX Oncology

Job title: Chief Scientific Officer


Dr. Hong Wan is currently Chief Scientific Officer at ALX Oncology, a clinical-stage immune-oncology company. Dr. Wan previously served as Senior Director, Biotechnology Clinical Development at Rinat (Pfizer), where she was responsible for the early development and translational medicine strategy across various therapeutic areas. Dr. Wan held previous leadership roles in Clinical Translational Medicine and Discovery Research at Pfizer, Wyeth Research, and Renovis.  Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.


Panel Discussion: Defining Metrics of Success with Macrophage-directed Therapeutics 9:30 am

Key questions to address: • What does success look like when manipulating macrophage phenotypes? • Is success defined through restructuring the tumor microenvironment or activating t cell infiltration to the tumor site? • What will be the most relevant strategy clinically addressing macrophages? • Define the most important parameters around this modality that will reflect…Read more

day: Day Two

Targeting CD47-SIRPa Myeloid Checkpoint Pathway to Enhance Innate & Adaptive Immunity Against Cancer without Hematological Toxicity 9:00 am

• Discuss how ALX148, a unique CD47 blocker which is a high affinity SIRPa fusion protein linked to an inactive Fc region of human immunoglobulin, is designed to maximize the clinical benefit of antibody-based therapies and its clinical development for a broad range of tumor types • Review preclinical studies where ALX148 bridges innate and…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.